Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pfizer

Share:
Related PFE
5 U.S. Large-Caps Facing Declining Revenue
Icagen Re-launched Through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D
PSA: Afrezza Is NOT Exubera (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), and raised its price target from $27.00 to $31.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Pfizer closed on Tuesday at $26.74.

Latest Ratings for PFE

DateFirmActionFromTo
Jun 2015JefferiesInitiates Coverage onOverweight
Jun 2015Piper JaffrayInitiates Coverage onOverweight
Apr 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters